Eagle takes sporadic flight on US Ryanodex nod
This article was originally published in Scrip
Executive Summary
The FDA granted Eagle Pharmaceuticals approval to market its orphan drug Ryanodex (dantrolene sodium) as a treatment for malignant hyperthermia (MH), an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible people.
You may also be interested in...
Keeping Track: Ayvakit Approval, Keytruda Supplement, NME Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Lower Doses Of Narcan, Linzess Approved; US FDA Receives Actemra, Ryanodex, Dextenza Submissions
The latest drug development news and highlights from our FDA Performance Tracker.
Eagle Hopes To Build On Bendamustine Success With Injectable Reformulations
With concentrated, lower-volume injectables, the specialty firm is finding larger patient bases for the cancer drug bendamustine and the muscle relaxant dantrolene.